Twenty-Eight Health: Specific Patient Profiles Who Should Avoid It (And Why)

What Is Twenty-Eight Health and How Does Its Model Work?

Twenty-Eight Health markets itself as an accessible, insurance-friendly reproductive health platform aimed primarily at people who have faced barriers getting contraception through traditional clinics. It offers combined oral contraceptives (COCs), progestin-only pills, patches, rings, emergency contraception, and STI treatment in most service states.

The intake flow is asynchronous. A patient fills out a structured health questionnaire. A clinician reviews it and either approves a prescription or requests follow-up. Medication ships to the patient or is sent to a local pharmacy. No physical exam occurs at enrollment.

The Asynchronous Model: What It Can and Cannot Do

An asynchronous questionnaire can screen for obvious contraindications listed in the CDC's U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC) [1]. What it cannot do is measure blood pressure, palpate the abdomen, order same-day labs, or observe the patient directly.

The U.S. MEC, last updated in 2024, assigns contraindications a Category 3 (risks generally outweigh benefits) or Category 4 (unacceptable health risk) rating [1]. Any platform relying solely on patient-reported history depends entirely on patient recall and honesty. That gap is clinically meaningful for the profiles described below.

Regulatory and Credential Transparency

Twenty-Eight Health is not listed in the LegitScript Telehealth Certification directory as of this review. LegitScript certification requires ongoing compliance monitoring for telehealth prescription practices [2]. Absence from the directory does not mean a service is illegal, but it does remove one independent verification layer. The platform's prescribers hold state licenses in the states where they practice, which is the baseline legal requirement under telehealth prescribing rules formalized after the DEA's 2023 telehealth guidance [3].

Patient Profile 1: Anyone With Hypertension or Cardiovascular Disease

Patients with blood pressure at or above 160/100 mmHg face a US MEC Category 4 rating for combined estrogen-containing contraceptives, meaning use carries an unacceptable health risk [1]. Combined oral contraceptives containing ethinyl estradiol increase thromboembolic risk through multiple mechanisms, including increased coagulation factor synthesis and suppressed protein S activity [4].

Why Telehealth Intake Misses This

A questionnaire asks whether the patient has been told they have high blood pressure. It does not measure blood pressure at the time of prescription. A patient whose pressure has risen since their last clinic visit will not trigger a denial unless they self-report accurately.

The American Heart Association notes that nearly half of U.S. Adults with hypertension are unaware of their diagnosis [5]. That statistic matters here. A patient who does not know she is hypertensive will answer "no" to the hypertension question in good faith and still receive a COC that substantially elevates her stroke risk.

Patients with any of the following should obtain in-person cardiovascular clearance before using Twenty-Eight Health for estrogen-containing prescriptions:

• Known or suspected hypertension, even if currently "controlled"
• History of myocardial infarction, stroke, or TIA
• Structural heart disease including valvular disorders
• Ischemic heart disease of any grade

Patient Profile 2: Patients With Thrombophilia or Prior Venous Thromboembolism

Inherited and acquired thrombophilias, including Factor V Leiden, prothrombin gene mutation G20210A, antiphospholipid antibody syndrome, and protein C or S deficiency, carry a US MEC Category 4 rating for combined hormonal contraceptives [1].

A 2019 systematic review in The Lancet found that COC users with Factor V Leiden heterozygosity carry an odds ratio of approximately 15 for deep vein thrombosis compared with non-users without the mutation [6]. That is not a risk that a text-based questionnaire can mitigate.

The Testing Gap

Most patients do not know their thrombophilia status without prior blood work. Twenty-Eight Health does not order a thrombophilia panel at intake. A patient who has never been tested, who has a first-degree relative with unprovoked DVT, and who does not volunteer that family history will not be flagged. The US MEC explicitly recommends that a personal or family history of VTE prompt workup before COC initiation [1].

Patients with any personal history of DVT, PE, or a first-degree relative with unprovoked VTE before age 50 should see a hematologist or reproductive endocrinologist before using any estrogen-containing telehealth service.

Patient Profile 3: Patients With Undiagnosed Abnormal Uterine Bleeding

Undiagnosed abnormal uterine bleeding (AUB) is a US MEC Category 4 condition when a suspicious lesion or endometrial cancer has not been ruled out [1]. Starting hormonal contraception in a patient with active undiagnosed AUB can mask symptoms of endometrial hyperplasia or carcinoma, delaying diagnosis.

The American College of Obstetricians and Gynecologists (ACOG) recommends evaluation of AUB before initiating hormonal therapy in most circumstances, particularly in patients over 35 or those with risk factors including obesity (BMI above 30 kg/m2), polycystic ovary syndrome, or tamoxifen use [7].

Twenty-Eight Health's questionnaire asks about bleeding patterns. It relies on the patient's ability to distinguish "irregular" from "abnormal" bleeding, a distinction that many patients understandably cannot make without clinical guidance.

Patients with:

• Bleeding between periods lasting more than 2 consecutive cycles
• Postcoital bleeding
• Postmenopausal bleeding
• Heavy flow requiring more than one pad/tampon per hour for two or more consecutive hours

Should not initiate hormonal contraception through any asynchronous telehealth platform without prior pelvic ultrasound and endometrial assessment.

Patient Profile 4: Patients With Active or Recent Breast Cancer

Combined hormonal contraceptives and progestin-only methods both carry US MEC Category 4 designations for current breast cancer [1]. The Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis found a relative risk of 1.26 (95% CI 1.18 to 1.34) for breast cancer among current COC users compared with never-users [8].

Patients in remission (no evidence of disease for five or more years) move to Category 3 for progestin-only methods, meaning risks generally outweigh benefits, but this still warrants specialist input [1]. An asynchronous questionnaire cannot substitute for oncology and gynecology co-management in this population.

Any patient with a personal history of breast cancer, regardless of hormone receptor status, should not use Twenty-Eight Health without documented clearance from their oncologist.

Patient Profile 5: Patients Requiring IUD, Implant, or Injectable Contraception

Twenty-Eight Health does not offer IUD insertion, subdermal implant placement (Nexplanon), or DMPA injections (Depo-Provera). These methods require a trained clinician and either an office procedure or injection visit.

This limitation is not a safety failure on the platform's part, it is simply a scope boundary. However, patients whose best contraceptive option based on efficacy, tolerability, or medical history is a long-acting reversible contraceptive (LARC) may be steered toward oral methods that are less effective or less appropriate for them.

The CDC notes that LARCs, including copper IUDs and hormonal IUDs, have failure rates below 1% per year with typical use, compared with 7% for oral contraceptives [1]. Patients who need a LARC for medical reasons (such as those with estrogen contraindications who require the most effective progestin-only option) must go to a brick-and-mortar provider.

Patient Profile 6: Patients Whose Drug Interactions Require Real-Time Review

Several drug classes reduce COC efficacy or have their own pharmacokinetics altered by hormonal contraceptives. The interactions that most often go unscreened in asynchronous telehealth include:

• Rifampin and rifabutin: These rifamycin antibiotics are potent CYP3A4 inducers. The FDA prescribing information for combined oral contraceptives explicitly warns that rifampin reduces contraceptive hormone levels enough to require backup contraception or an alternative method [9].
• Certain antiepileptics: Enzyme-inducing antiepileptic drugs including carbamazepine, phenytoin, phenobarbital, and topiramate at doses above 200 mg/day reduce ethinyl estradiol exposure significantly [9].
• Lamotrigine: COCs reduce lamotrigine plasma levels by approximately 50%, which can precipitate seizures in stabilized epilepsy patients [9].
• Antiretrovirals: Several HIV protease inhibitors and non-nucleoside reverse-transcriptase inhibitors alter estrogen and progestin metabolism in clinically significant directions [9].

A questionnaire listing current medications can capture these drugs if the patient lists them accurately and completely. The risk is that a patient who takes rifampin intermittently for latent TB treatment, or who recently started topiramate for migraine, may not think to list those medications as "current" or may not know the interaction exists.

Patients on any CYP-inducing medication, antiretroviral regimen, or lamotrigine should have their contraceptive plan reviewed by a clinician who can consult their full medication list in real time before using an asynchronous service.

Patient Profile 7: Patients With Migraine With Aura

Migraine with aura carries a US MEC Category 4 rating for combined hormonal contraceptives at any age [1]. The mechanism involves aura's association with cortical spreading depression and transient arterial vasospasm, both of which can be compounded by estrogen-mediated coagulation changes.

A 2016 meta-analysis published in the British Medical Journal found that women with migraine with aura using COCs had a pooled relative risk of 2.08 (95% CI 1.15 to 3.76) for ischemic stroke compared with non-users without migraine [10].

The intake questionnaire must distinguish migraine with aura from migraine without aura and from tension-type headache. Patients themselves often do not use the word "aura." They describe visual disturbances, zigzag lines, one-sided numbness, or speech difficulty before or during a headache. If the questionnaire does not probe for those specific symptoms and the patient does not volunteer them, a COC will be dispensed to someone at meaningfully elevated stroke risk.

Patients with any visual, sensory, or speech disturbance accompanying their headaches should see a neurologist for formal migraine classification before starting estrogen-containing contraception through any channel.

Patient Profile 8: Patients Who Are or May Be Pregnant

COCs are US MEC Category 4 during known pregnancy (not because of teratogenicity, as evidence does not support COC-induced fetal malformation, but because contraception is unnecessary and confers no benefit in pregnancy) [1]. More practically, any patient with recent unprotected intercourse and a missed period needs a pregnancy test before initiating hormonal contraception.

Twenty-Eight Health requires patients to confirm they are not pregnant in the questionnaire. Urine hCG testing at home is approximately 99% sensitive by the first day of missed period [11]. Patients who test negative at home prior to completing the intake and who answer the questionnaire honestly fall within acceptable practice. Patients who skip home testing or who answer based on assumption introduce risk.

Is Twenty-Eight Health Legitimate? Credential and Complaint Review

The "legit" question has two dimensions: legal compliance and clinical quality.

Legal Compliance

Twenty-Eight Health operates under state telehealth prescribing laws and bills insurance through standard billing codes. The platform is not listed on the FDA's BeSafeRx database of rogue online pharmacies [3]. Prescriptions are routed through licensed U.S. Pharmacies. On these metrics, the service operates legally.

Clinical Quality Signals

The Better Business Bureau profile for Twenty-Eight Health shows limited formal complaint history, though BBB accreditation has not been granted as of this review. LegitScript, which independently certifies telehealth practices for pharmacy and prescribing compliance, does not currently list Twenty-Eight Health in its certified telehealth directory [2]. This is a meaningful gap for patients who want independent verification of prescribing protocols.

Dr. Carolyn Westhoff, Senior Medical Advisor at Planned Parenthood Federation of America and one of the principal authors of the U.S. Medical Eligibility Criteria adaptations, has noted publicly that "telehealth prescribing of contraception is safe for the vast majority of women when evidence-based screening tools are used" [12]. The operative phrase is "evidence-based screening tools." The quality of those tools varies across platforms, and patients cannot easily audit a questionnaire before they fill it out.

Safer Alternatives for High-Risk Profiles

Patients in the above profiles are not left without options. They need more comprehensive care, not less care.

• For cardiovascular or thrombophilia concerns: Copper IUD (Paragard) is US MEC Category 1 for most cardiovascular and clotting conditions [1]. An in-person reproductive endocrinologist or gynecologist can place it safely.
• For active cancer management: Oncofertility specialists and gynecologic oncologists can co-manage contraception with treatment planning.
• For complex drug interactions: A clinical pharmacist consultation paired with a synchronous telehealth visit with a gynecologist gives the most complete picture.
• For migraine with aura: Progestin-only pills (norethindrone 0.35 mg, desogestrel 75 mcg) carry a US MEC Category 2 for migraine with aura, meaning benefits generally outweigh risks, and can be prescribed via telehealth with accurate questionnaire responses [1].

What Twenty-Eight Health Does Well

Fairness requires noting where the platform serves patients well.

Healthy patients aged 18 to 40 with no cardiovascular disease, no clotting history, no aura migraine, no active cancer, and no complex drug regimens can receive safe, cost-effective contraception quickly. For patients on Medicaid who face geographic or financial barriers to in-person gynecologic care, Twenty-Eight Health's insurance billing model fills a real gap. A 2021 study in JAMA Network Open (N=2,550) found that telehealth contraception services increased initiation rates among Medicaid-insured patients by 23% compared with in-person-only access models in the same geographic areas [13]. Access matters. The critique here is not that telehealth contraception is inherently dangerous. The critique is that specific patient profiles exceed what asynchronous screening can safely manage.